Metabolic Dysfunction–Associated Steatotic Liver Disease and Concomitant Viral Diseases (Human Immunodeficiency Virus, Hepatitis B Virus)

Metabolic dysfunction–associated steatotic liver disease (MASLD) increasingly coexists with chronic viral infections, particularly HIV and hepatitis B virus (HBV), creating complex and evolving liver disease phenotypes. This session examines how metabolic dysfunction modifies liver disease progression, fibrosis risk, and clinical outcomes in persons with concomitant HIV and/or HBV infection. The impact of viral infection and antiviral therapies, in turn, influence MASLD natural history. Topics include: epidemiology and mechanisms of disease synergy; challenges in fibrosis assessment and risk stratification; and practical management considerations for hepatologists caring for individuals with overlapping metabolic and viral liver disease. Presenters emphasize translating emerging data into clinical decision-making for diverse patient populations.